PRIMARY MEDIASTINAL B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immune-Guiding antibody aims to clean up remaining cancer cells after transplant
Disease control OngoingThis early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New immunotherapy combo tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Promising lymphoma combo trial pulled before it even started
Disease control TerminatedThis study was designed to test a combination of two drugs—golcadomide and nivolumab—in people with non-Hodgkin lymphoma whose cancer did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combo could shrink tumors. However, the tri…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising lymphoma combo trial pulled before it began
Disease control TerminatedThis study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control OngoingThis phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo aims to boost CAR-T success in hard-to-treat lymphomas
Disease control TerminatedThis study tests whether adding an experimental drug called E7777 before standard CAR-T therapy can help people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 30 participants will receive E7777 followed by chemotherapy and a CAR-T produc…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radiation-Free hope for mediastinal lymphoma patients
Disease control OngoingThis study looks at whether people with a type of lymphoma (primary mediastinal large B-cell lymphoma) can safely avoid radiation therapy after standard chemoimmunotherapy if a PET/CT scan shows no active tumor. About 540 patients who had a negative PET/CT after treatment were ra…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: NA • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can statins and steroids tame CAR-T's brain risks?
Disease control OngoingThis early-phase trial tests whether giving simvastatin (a cholesterol drug) and dexamethasone (a steroid) can safely prevent nerve-related side effects from axicabtagene ciloleucel (Axi-Cel) CAR-T therapy in adults with certain types of lymphoma. The study includes 37 participan…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells take on childhood leukemia and lymphoma
Disease control OngoingThis study is testing a therapy where a child's own immune cells are modified in a lab to recognize and attack cancer cells. The treatment is for children with B-cell acute lymphoblastic leukemia or certain types of lymphoma that have come back or not responded to standard treatm…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
15-Year watch begins for CAR t cell therapy patients
Knowledge-focused OngoingThis study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Sponsor: Adicet Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Blood test may replace scans for lymphoma monitoring
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Blood test may replace CT scans for lymphoma patients
Knowledge-focused OngoingThis study looks at whether a blood test can spot signs of lymphoma coming back after chemotherapy, possibly earlier than regular CT scans. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could …
Matched conditions: PRIMARY MEDIASTINAL B CELL LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC